You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

MSI-High

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Neoadjuvant Envafolimab in Resectable and Locally Advanced

Not yet recruiting
  • Locally Advanced Rectal Carcinoma
  • MSI-High
  • (no location specified)
Dec 9, 2022

Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)

Recruiting
  • Gastric Cancer
  • Microsatellite Instability
  • Milan, Italy
    Fondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022

POLE Exonuclease Mutant Colon Cancer, Microsatellite Instability, Stage III Colon Cancer Trial in Sutton (Avelumab)

Terminated
  • POLE Exonuclease Mutant Colon Cancer
  • +2 more
  • Sutton, Surrey, United Kingdom
    Royal Marsden NHS Foundation Trust
Oct 5, 2022

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in ZhengZhou (Cadonilimab

Not yet recruiting
  • Colorectal Cancer
  • +3 more
  • Cadonilimab (®), a PD-1/CTLA-4 bi-specific antibody
  • ZhengZhou, Henan, China
    Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZho
Jun 18, 2023

Adenocarcinoma - GEJ, Gastric Adenocarcinoma Trial (Dostarlimab)

Not yet recruiting
  • Adenocarcinoma - GEJ
  • Gastric Adenocarcinoma
  • (no location specified)
Sep 26, 2023

Multiple Cancer, Colorectal Cancer Trial (MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 mAb neoadjuvant

Not yet recruiting
  • Multiple Cancer
  • Colorectal Cancer
  • MSI-H/MSS (dMMR/pMMR) mixed sMPCC: combination of mFOLFOX6+PD-1 monoclonal antibody neoadjuvant therapy
  • All-MSI-H (dMMR) sMPCC: single-drug PD-1 monoclonal antibody neoadjuvant therapy
  • (no location specified)
Aug 20, 2023

DOstarlimab in Recurrent or dMMR/MSI-H Endometrial Cancer

Not yet recruiting
  • Endometrial Cancer
  • (no location specified)
Feb 14, 2023

MSI-H Trial in Guangzhou (IBI310, Radical surgery, Sintilimab)

Not yet recruiting
  • MSI-H
  • Guangzhou, Guangdong, China
    Sun Yat-sen University Cancer Center
May 26, 2023

Colorectal Cancer Trial in Essen (Atezolizumab)

Recruiting
  • Colorectal Cancer
  • Essen, Germany
    Westdeutsches Tumorzentrum
Feb 14, 2022

Colorectal Carcinoma Trial (mFOLFOX6, FOLFIRI, pembrolizumab)

Active, not recruiting
Has Results
  • Colorectal Carcinoma
  • (no location specified)
Oct 28, 2022

Colorectal Cancer Stage IV, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial (Cadonilimab)

Not yet recruiting
  • Colorectal Cancer Stage IV
  • +2 more
  • (no location specified)
Jun 19, 2022

MSI-H/dMMR Solid Tumor Trial in Guangzhou (AK104)

Terminated
  • MSI-H/dMMR Solid Tumor
  • Guangzhou, Guangdong, China
    Sun Yat-Sen University Cancer Center
Oct 17, 2022

Recurrent/Metastatic Gastric Cancer Trial in Seoul (Nivolumab, Paclitaxel)

Completed
  • Recurrent/Metastatic Gastric Cancer
  • Nivolumab, Paclitaxel
  • Seoul, Korea, Republic of
    Yonsei University Health System, Severance Hospital
Sep 9, 2022

Colorectal Cancer Trial in Beijing (IBI310 (anti-CTLA-4 antibody), Sintilimab(anti-PD-1 antibody))

Active, not recruiting
  • Colorectal Cancer
  • IBI310 (anti-CTLA-4 antibody)
  • Sintilimab(anti-PD-1 antibody)
  • Beijing, China
    Beijing cancer hospital
Sep 15, 2022

Colorectal Carcinoma Trial in Guangzhou (Sintilimab, Oxaliplatin, capecitabine)

Recruiting
  • Colorectal Carcinoma
  • Guangzhou, China
    Sun Yat-sen University
Dec 29, 2022

Melanoma Stage IV, Head and Neck Squamous Cell Carcinoma, Cutaneous Squamous Cell Carcinoma Trial in Oslo (Fecal Microbiota

Recruiting
  • Melanoma Stage IV
  • +4 more
  • Fecal Microbiota Transplant (FMT)
  • Oslo, Norway
    Oslo University Hospital
Aug 29, 2022

Adenocarcinoma of the Pancreas, Adenocarcinoma of the Colon, Adenocarcinoma of the Rectum Trial in Lyon (Pembrolizumab,

Active, not recruiting
  • Adenocarcinoma of the Pancreas
  • +2 more
  • Lyon, France
    Centre Léon Bérard
Mar 17, 2022

Microsatellite Stable Colorectal Cancer, Pancreatic Cancer, MSI High Colorectal Cancer Trial in Boston (Nivolumab, Ipilimumab,

Recruiting
  • Microsatellite Stable Colorectal Cancer
  • +2 more
  • Boston, Massachusetts
    Massachusetts general Hospital
Mar 24, 2021

Colorectal Cancer, Mismatch Repair-deficient (dMMR), Microsatellite Instability-high (MSI-H) Trial in Guangzhou (Neoadjuvant

Recruiting
  • Colorectal Cancer
  • +3 more
  • Neoadjuvant therapy with PD-L1 inhibitor
  • Guangzhou, Guangdong, China
    the Third Affiliated Hospital of Sun Yat-Sen University
May 10, 2022

Malignancy, Malignant Tumor, Lymphoproliferative Disorders Trial in United Kingdom (Atezolizumab)

Not yet recruiting
  • Malignancy
  • +8 more
  • Belfast, United Kingdom
  • +25 more
Mar 14, 2023

Digestive System Cancers Trial in Beijing (KN046, Regorafenib, Apatinib)

Recruiting
  • Digestive System Cancers
  • Beijing, China
    Peking University Cancer Hospital
Oct 25, 2023

Solid Tumor Trial in Beijing (KN035)

Recruiting
  • Solid Tumor
  • KN035
  • Beijing, Beijing, China
    Peking University Cancer Hospital, Peking University
Apr 5, 2022

Colorectal Cancer, Microsatellite Instability High Trial in Guangzhou (PD-1 inhibitor plus VEGF inhibitors)

Recruiting
  • Colorectal Cancer
  • Microsatellite Instability High
  • PD-1 inhibitor plus VEGF inhibitors
  • Guangzhou, Guangdong, China
    651 Dongfeng Road East
May 27, 2022

Metastatic Colorectal Cancer Trial in China (HX008, Investigator's Choice Chemotherapy)

Not yet recruiting
  • Metastatic Colorectal Cancer
  • HX008
  • Investigator's Choice Chemotherapy
  • Hefei, Anhui, China
  • +9 more
Dec 8, 2022

Solid Tumors, Identified by NGS, PCR or IHC Trial in United States (Pembrolizumab)

Recruiting
  • Solid Tumors
  • Identified by NGS, PCR or IHC
  • Basking Ridge, New Jersey
  • +6 more
Oct 7, 2022